← Leaderboards
Alan Stitt
New York University School Of Medicine
$658,376
Attributed
$1,975,128
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $533.4K · FY2020–23$1M$750K$500K$250K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$1,975,128 · 1
By mechanism
R01$1,975,128 · 1
Top collaborators
- Ana Rodriguez7 shared
- Thomas Walther7 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Ana Rodriguez$8,975,691
- Thomas Walther$1,480,582
- Hannah L Klein$8,495,364
- Josef Coresh$115,254,828
- Daniel B Rifkin$20,829,657
Others in their field
Other Emerging Leaders on “Foundations”
- Valerie Koch · University Corporation For Atmospheric Res$265,601,376
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- John E West · University Of Texas At Austin$131,399,667
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter K Fritschel · California Institute Of Technology$78,820,000
Research focus
FoundationsFutureErythrocytesFinancial SupportFunding AgencyAngiotensin ReceptorEdemaEndotheliumAngiotensin IiExperimental StudyAgonistFundingBloodBlood - Brain Barrier AnatomyAntimalarialsClinical TrialsAffectEndothelial CellsBrainBrain Endothelial CellCerebral MalariaClinical TreatmentCellsG-Protein-Coupled Receptors
Grant awards (7)
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$435,542
R01 · FY2023 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$37,154
R01 · FY2023 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$435,542
R01 · FY2022 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$97,903
R01 · FY2022 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$435,542
R01 · FY2021 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$97,903
R01 · FY2021 · HL
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists$435,542
R01 · FY2020 · HL